by DSA Consultants | Apr 21, 2016 | Announcement, Cosmetics
In the December 2015 update to the Cosmetic Ingredient Hotlist, a restriction was added to the Methylisothiazolinone/Methylchloroisothiazolinone (MI/MCI) entry. MI/MCI when used in combination is a prohibited substance in leave-on cosmetic products. An implementation...
by DSA Consultants | Apr 14, 2016 | GMP
DSA was recently by hired by one of our manufacturing clients in in Asia to determine if their manufacturing documents would meet Health Canada expectations. Health Canada requires that all GMP records are made available in English or French. The first part of the...
by DSA Consultants | Apr 4, 2016 | Announcement, Medical Devices
Health Canada has announced that effective immediately evidence will be required to demonstrate that all hazards associated with thermal damage to the skin are eliminated or appropriately mitigated for light emitting medical devices. Affected devices include devices...
by DSA Consultants | Apr 4, 2016 | Announcement, Drugs
All non-prescription Category IV Monograph product (DINF) applications must include the new monograph attestation form. Due to unfavorable results of the monograph attestation pilot, Health Canada has put in place processes to ensure that all DINF applications comply...
